Hologic Expands Healthcare Investme...(ity. These forward looking statements ar...),Health

Date:10/19/2009

ity. These forward looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

    Contacts: James Culley, Ph.D.       SK Tse (Siu-Kai Tse)
              Corporate Marketing       HK Managing Director, Far East Sales
              Hologic, Inc.             Hologic Asia Pacific Limited
              Boston, Mass. USA         Hong Kong, China
              +1(302) 528-1312          +(852) 3748 7700
              jim.culley@hologic.com    siu-kai.tse@hologic.com

SOURCE Hologic, Inc.

'/>"/>

SOURCE Hologic, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
2. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
3. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
6. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
7. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
8. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
9. Raptor Pharmaceutical Expands Board of Directors
10. Intermountain McKay-Dee Hospital Center Expands Real-Time Locating Solution From Versus Technology, Inc.
11. Lupin Expands Branded Play